MDT earnings analysis — 8-K, statement tables美敦力公司 (MDT) 财报解读 — 8-K、statement tables
Medtronic plc (MDT) FY26 Q4 and Full Year Earnings Follow-Up Analysis
1. Actual vs. Consensus Results: Per the official PR Newswire release and SEC 8-K Exhibit 99.1, Q4 FY26 revenue totaled $9.8B, exceeding the consensus estimate of $9.6B. Non-GAAP diluted EPS came in at $1.55, ahead of prior guidance, with GAAP diluted EPS at $0.96. The initial snapshot listed EPS actual as unreported, but final results beat consensus estimates.
2. Revenue Quality and Profitability: Full FY26 revenue reached $36.36B, up 8.4% reported and 5.8% organic, marking the strongest annual top-line growth in 10 years. Q4 organic revenue growth hit 6.6%, 90 bps ahead of implied guidance. Key business segments: Cardiac Ablation Solutions revenue rose 78% globally, with U.S. growth at 124% and an 8-point U.S. share gain; Cardiovascular grew 10.1%, and Diabetes revenue rose 15%. The company also submitted FDA filings for Hugo™ RAS and received clearance for Stealth AXiS Surgical System, completed the CathWorks acquisition, and announced agreements to acquire Scientia Vascular and SPR Therapeutics. The updated Q3 financial snapshot (period ended January 23, 2026) shows a 64.9% gross margin; Q4 GAAP operating margin was 19.1%, with non-GAAP operating margin at 25.5%, and GAAP EPS up 17.1% year-over-year.
3. Cash Flow and Shareholder Returns: FY26 operating cash flow was $7.33B, with free cash flow at $5.43B and a 76% free cash flow conversion rate. End-of-year cash and investments totaled $9.2B. The company announced its 49th consecutive annual dividend increase, raising Q1 FY27 quarterly dividend to $0.72 per share, for an annualized $2.88 per share.
4. Guidance: Medtronic provided FY27 organic revenue growth guidance of 6.75% to 7.25%, with no additional non-GAAP financial guidance disclosed.
5. GAAP vs. Non-GAAP Differences: Q4 non-GAAP operating margin fell 230 bps year-over-year due to MiniMed Blackstone payment and tariff impacts; full-year non-GAAP operating margin fell 130 bps, or 150 bps on a constant currency basis.
6. Unresolved Investor Questions: No earnings call transcript was available, so segment-specific backlog/deferred revenue data, capex allocation plans, and additional FY27 EPS guidance remain unreported.
美敦力(MDT)2026财年第四财季及全年业绩跟进分析
1. 实际业绩与预期对比：根据官方新闻稿（PR Newswire）及SEC 8-K附件文件，2026财年第四财季营收达98亿美元，超出市场共识预期的96亿美元；非GAAP摊薄每股收益1.55美元，超出此前指引，GAAP摊薄EPS为0.96美元。初始快照曾标注EPS实际值未披露，最终实际业绩均超出预期。
2. 营收质量与盈利能力：2026财年全年营收363.6亿美元，按报告口径增长8.4%，有机增长5.8%，为10年来最高年度营收增速。第四财季有机营收增长6.6%，超出隐含指引90个基点。核心业务表现亮眼：心脏消融解决方案全球营收同比增长78%，美国市场增长124%，美国份额提升8个点；心血管业务增长10.1%，糖尿病业务营收增长15%。公司同期提交了Hugo™ RAS的FDA申请，获得Stealth AXiS外科系统的FDA清关，完成CathWorks收购并宣布收购Scientia Vascular和SPR Therapeutics。第三财季（截至2026年1月23日，更新财报快照）毛利率为64.9%；第四财季GAAP营业利润率19.1%，非GAAP营业利润率25.5%，GAAP EPS同比增长17.1%。
3. 现金流与股东回报：2026财年经营现金流73.3亿美元，自由现金流54.3亿美元，自由现金流转换率达76%。年末现金及投资余额92亿美元，公司宣布连续第49年上调股息，2027财年第一季度季度股息升至0.72美元/股，年化股息2.88美元/股。
4. 业绩指引：公司披露2027财年有机营收增长指引区间为6.75%至7.25%，未披露其他非GAAP财务指引细节。
5. GAAP与非GAAP差异：第四财季非GAAP营业利润率同比下滑230个基点，受MiniMed Blackstone付款及关税影响；全年非GAAP营业利润率同比下滑130个基点，固定汇率口径下滑150个基点。
6. 未明确事项：未获取业绩电话会议 transcript，缺少细分业务订单/递延收入数据、资本支出具体分配计划，以及2027财年EPS等额外财务指引。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。